<![CDATA[Platinum-based chemotherapy is the first-line treatment for patients with advanced NSCLC. Cancer treatment is known to be time-consuming and expensive, resulting in numerous studies evaluating the costs of commonly used chemotherapy regimens. This narrative review aims to analyze and compare two of the most widely used regimens, cisplatin-paclitaxel and cisplatin-gemcitabine, in terms of costs and clinical outcomes. Articles were searched through various databases, including PubMed, Science Direct, the Cochrane Library, Scopus, and Google Scholar, used a combination of keywords ("cisplatin-paclitaxel" OR "cisplatin-gemcitabine") AND "advanced NSCLC" AND "cost", with a publication timeframe from 2000 to the most recent year of the search. Articles were reviewed based on topic relevance and content suitability. Articles were selected based on topic relevance and compliance with the inclusion criteria, then data related to treatment costs were extracted and compared descriptively. Six of the seven selected articles showed that the cisplatin-gemcitabine regimen resulted in lower total therapy costs than cisplatin-paclitaxel. Although the clinical outcomes produced by both regimens were generally comparable, cisplatin-gemcitabine tended to have slightly higher efficacy, but not significantly different. These findings suggest that cisplatin-gemcitabine may be a more cost-effective alternative in the treatment of patients with advanced NSCLC. The results of this review can be used as supporting data for consideration in selecting chemotherapy regimens for patients with advanced NSCLC.]]>
